CompanyGraph
At a glance
- Depends onUpstream position: supplies 6 industries, depends on 3
- ScaleRevenue is $0, lower than 95% of all stocks globally
- FinancialsAltman Z-Score -4.04: distress zone
- Interpretations1 currently firing — 1
Sign in to view price data.
Sign inThe reported statements, read against the company's own industry.
Financials view
Market Capitalization
384.37MUSDvs all stocks (USD)
Revenue (TTM)
0.00USDvs all stocks (USD)
Profit Margin
0.00%vs Biotechnology peers
Beta
0.8370xvs all stocks
52-Week Change
13.50%vs all stocks
Market Capitalization
384.37MUSDvs all stocks (USD)
Enterprise Value
189.61MUSDvs all stocks (USD)
Forward P/E
-3.14xvs Biotechnology peers
Price to Book (MRQ)
2.44xvs Biotechnology peers
Enterprise to EBITDA
-1.10xvs Biotechnology peers
Profit Margin
0.00%vs Biotechnology peers
Operating Margin
0.00%vs Biotechnology peers
Return on Assets (TTM)
-56.92%vs Biotechnology peers
Return on Equity (TTM)
-109.83%vs Biotechnology peers
Revenue (TTM)
0.00USDvs all stocks (USD)
Revenue per Share (TTM)
0.00USDUpdated Jul 19, 2026Gross Profit (TTM)
0.00USDvs all stocks (USD)
EBITDA (TTM)
-172.10MUSDvs all stocks (USD)
Net Income (TTM)
-166.00MUSDvs all stocks (USD)
Operating Cash Flow (TTM)
-131.28MUSDvs all stocks (USD)
Levered Free Cash Flow (TTM)
-71.31MUSDvs all stocks (USD)
Trailing Annual Dividend Rate
0.00USDUpdated Jul 19, 2026Trailing Annual Dividend Yield
0.00%vs all stocks
Payout Ratio
0.00%vs Biotechnology peers
Revenue
0.00USDFY2025 · Dec 31, 2025Operating Income
-172.50MUSDvs all stocks (USD)
Pre-tax Income
-165.67MUSDFY2025 · Dec 31, 2025Net Income
-165.67MUSDFY2025 · Dec 31, 2025EBIT
-172.50MUSDFY2025 · Dec 31, 2025EBITDA (Income Statement)
-172.15MUSDFY2025 · Dec 31, 2025Research & Development
154.22MUSDFY2025 · Dec 31, 2025Selling, General & Administrative
18.27MUSDFY2025 · Dec 31, 2025EPS (Basic)
-2.27USDFY2025 · Dec 31, 2025EPS (Diluted)
-2.27USDFY2025 · Dec 31, 2025Basic Shares Outstanding
72.95MSharesFY2025 · Dec 31, 2025Diluted Shares Outstanding
72.95MSharesFY2025 · Dec 31, 2025Net Income from Continuing Operations
-165.67MUSDFY2025 · Dec 31, 2025Operating Cash Flow
-155.74MUSDFY2025 · Dec 31, 2025Free Cash Flow
-155.83MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents (End of Period)
86.02MUSDFY2025 · Dec 31, 2025Starting Profit (CF Statement)
-165.67MUSDFY2025 · Dec 31, 2025Depreciation & Amortization
350.00KUSDFY2025 · Dec 31, 2025Stock-based Compensation
7.00MUSDFY2025 · Dec 31, 2025Other Non-cash Items
-281.00KUSDFY2025 · Dec 31, 2025Change in Accounts Payable (CF)
2.79MUSDFY2025 · Dec 31, 2025Change in Other Assets/Liabilities
73.00KUSDFY2025 · Dec 31, 2025Capital Expenditures
-91.00KUSDFY2025 · Dec 31, 2025Purchase of Investments
-83.60MUSDFY2025 · Dec 31, 2025Sale of Investments
184.00MUSDFY2025 · Dec 31, 2025Net Investing Cash Flow
100.31MUSDFY2025 · Dec 31, 2025Net Financing Cash Flow
65.09MUSDFY2025 · Dec 31, 2025Shares Outstanding
103.88MSharesUpdated Jul 19, 2026Float Shares
59.94MSharesUpdated Jul 19, 2026Shares Short
12.19MSharesUpdated Jul 19, 2026Short Ratio
4.09daysvs all stocks
Short % of Shares Outstanding
18.13%vs all stocks
% Held by Insiders
1.15%vs all stocks
% Held by Institutions
86.15%vs all stocks
Total Cash (MRQ)
200.38MUSDvs all stocks (USD)
Total Cash per Share (MRQ)
1.92USDUpdated Jul 19, 2026Total Debt (MRQ)
3.78MUSDvs all stocks (USD)
Total Debt to Equity (MRQ)
0.0239xvs Biotechnology peers
Current Ratio (MRQ)
4.29xvs Biotechnology peers
Book Value per Share (MRQ)
1.51USDUpdated Jul 19, 2026Total Assets
145.84MUSDvs all stocks (USD)
Total Current Assets
142.02MUSDFY2025 · Dec 31, 2025Total Liabilities
67.76MUSDFY2025 · Dec 31, 2025Total Non-current Assets
3.82MUSDFY2025 · Dec 31, 2025Total Non-current Liabilities
2.96MUSDFY2025 · Dec 31, 2025Total Current Liabilities
64.80MUSDFY2025 · Dec 31, 2025Cash & Cash Equivalents
85.41MUSDFY2025 · Dec 31, 2025Other Short-term Investments
51.44MUSDFY2025 · Dec 31, 2025Accounts Payable
5.22MUSDFY2025 · Dec 31, 2025Short-term Debt
1.10MUSDFY2025 · Dec 31, 2025Long-term Debt
2.96MUSDFY2025 · Dec 31, 2025Common Stock (Book)
83.00KUSDFY2025 · Dec 31, 2025Retained Earnings
-434.83MUSDFY2025 · Dec 31, 2025Total Shareholders' Equity
78.08MUSDvs all stocks (USD)
52-Week Low
2.71USDUpdated Jul 19, 202652-Week High
6.42USDUpdated Jul 19, 202652-Week Change
13.50%vs all stocks
Beta
0.8370xvs all stocks
50-Day MA
3.58USDUpdated Jul 19, 2026200-Day MA
3.93USDUpdated Jul 19, 2026Avg 10-Day Volume
2.10MSharesUpdated Jul 19, 2026Avg 30-Day Volume
2.76MSharesUpdated Jul 19, 2026Diluted EPS (TTM)
-2.12USDUpdated Jul 19, 2026Other Income / Expense
6.82MUSDFY2025 · Dec 31, 20251 interpretation currently present — each is a set of fired observations whose alignment reads as one structural pattern. Click an observation to see the numbers behind it.
Screen for these patternsWhere is this company structurally exposed?
Ulcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
It sits well below its peak, and the fall has been both deep and long.
An interpretation is present only while every observation it reads stays fired (score ≥ 70). It describes what the aligned readings show — never a verdict, never a prediction.
Shared structure with peers — never a ranking.
Relationships view
Structural observations derived from financial data, industry benchmarks, and supply chain position.
Structural Tensions
Looks liquid, but the distress score says otherwiseNotable
Current Ratio: 4.29Altman Z-Score: -4.04
Financial Health
Altman Z-Score -4.04: distress zoneCritical
Altman Z-Score: -4.04
Low earnings qualitySignificant
Earnings Quality Score: -0.63
Supply Chain
Upstream position: supplies 6 industries, depends on 3Notable
Outgoing: 6.00Incoming: 3.00
Scale
Revenue is $0, lower than 95% of all stocks globallySignificant
Revenue (USD): 0.00Global P5: 30,274,777.221
Companies that share the same coordination system — how they create, deliver, or capture value.
Chengdu Huasun Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Upstream Bio, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Hangzhou Tianmu-Shan Pharmaceutical Enterprise Co., Ltd.
Tier 1ProductionApproval-Gated PipelineRuleFlow
Jilin Province Xidian Pharmaceutical Inc.
Tier 1ProductionApproval-Gated PipelineRule
Atea Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Sutro Biopharma, Inc.
Tier 1ProductionApproval-Gated PipelineRuleRisk
Compass Therapeutics Inc.
Tier 1ProductionApproval-Gated PipelineRule
PureTech Health plc
Tier 1ProductionApproval-Gated PipelineRiskInterface
Kontour Xi'an Medical Technology Co. Ltd.
Tier 1ProductionApproval-Gated PipelineRule
Rocket Pharmaceuticals Inc.
Tier 1ProductionApproval-Gated PipelineRule
Companies that share active interpretations — structural patterns currently present in both stocks.
Ceres Power Holdings plc
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Lotte Tour Development Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated
Cheryong Electric Co., Ltd.
1 interpretationUlcer Index Elevated, Drawdown From Peak Significant, 20-Week Volatility Elevated